USPTO Patent Application for Tyk2 Inhibitor Dosage Forms

ChangeBridge: Patent Apps - Pharma (A61K)

Published December 2nd, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083734A1) filed on December 2, 2025, for "Dosage Forms for Tyk2 Inhibitors." The application describes stable and bioavailable formulations, including spray-dried dispersions, of a specific Tyk2 inhibitor (BMS-986165) in a solid polymer matrix. These formulations are intended for the treatment of autoimmune and auto-inflammatory diseases such as inflammatory bowel disease and psoriasis.

As this is a patent application, it does not impose direct compliance obligations on pharmaceutical companies. However, it signifies potential future intellectual property protection and innovation in the treatment of autoimmune diseases. Companies operating in this space should monitor patent filings for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

DOSAGE FORMS FOR TYK2 INHIBITORS

Application US20260083734A1 Kind: A1 Mar 26, 2026

Inventors

Sherif Ibrahim Farag Badawy, Jonathan R. Brown, Candice Y. Choi, Christoph Gesenberg, Vivienne Gray, John Wynne Jones, Umesh Kestur, Balvinder S. Vig, Xiaotian S. Yin, Christopher A. Zordan, Corey Bloom, Ian Yates

Abstract

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis: